Abstract
Introduction:
Patients with mitochondrial disorders always show neurological deficits. However, the diversity of clinical manifestations, genetic heterogeneity and threshold effect caused by maternal heredity make its diagnosis very challenging.
Case presentation:
A 30-year-old female presented to our neurology department with a recurrence of symmetrical weakness proximally in the lower extremities. Seven years ago, the patient had a sudden onset of persistent weakness in bilateral proximal lower extremities, along with elevated creatinine kinase (CK) and CK-MB. Given the diagnosis of Guillain-Barre syndrome, she was treated with high-dose glucocorticoid (GC) therapy at the local hospital and recovered. After admission to our hospital, laboratory analysis revealed elevated CK and alpha-hydroxybutyrate dehydrogenase in serum. Electrocardiography showed sinus tachycardia and left high ventricular voltage. Electromyography (EMG) and evoked potential (EP) suggested peripheral neurogenic damage of the upper and lower extremities with myogenic wear. Chronic inflammatory demyelinating polyneuropathy (CIDP) was initially considered, but neurological symptoms were not significantly improved with glucocorticoid shock therapy. An elevated level of lactate was found. The short-tau inversion recovery (STIR) axial magnetic resonance image (MRI) revealed mild hyperintensities, indicating muscle edema. Meanwhile, muscle biopsies suggested pathological changes in mitochondrial disorders (MIDs) and neuronal damage. Further mitochondrial genome analysis revealed a heteroplasmic m3271 T>C mutation in the mitochondrial tRNA-Leu gene (UUR). Collectively, the patient was finally diagnosed with mitochondrial disorder and apparently improved after the corresponding treatment to regulate energy metabolism.
Conclusions:
To our knowledge, it's the first report about MELAS with 3271 mutation that have only shown peripheral nerve motion impairment. Proximal weakness is also common in CIDP. In the context of this patient's experience, mitochondrial genome analysis provides an auxiliary criterion for differential diagnosis between MIDs and CIDP. In the meantime, we discussed the clinical effect of GCs on MIDs.
Introduction
Mitochondrial diseases are caused by mutations in nuclear or mitochondrial genes, characterized by defects in oxidative phosphorylation (1). Mitochondrial diseases have diverse clinical manifestations, of which neurological deficits are the most common symptoms and probably make the greatest contribution to morbidity and mortality (2). However, the diversity of clinical manifestations, genetic heterogeneity and threshold effect caused by maternal heredity make its diagnosis very challenging. Mitochondrial encephalopathy with lactic acid and stroke-like episodes is one of the most common maternal mitochondrial diseases. Herein, we report the first patient of MELAS with T3271C mitochondrial mutation who presented only as impaired movement.
Patient information
A 30-year-old female presented to our neurology department with a recurrence of symmetrical weakness proximally in the lower extremities. Seven years ago, the patient had a sudden onset of persistent weakness in the bilateral proximal lower extremities. At the time, she was able to stand with assistance and walk on her own. She then visited the local medical clinic for the first time at the age of 23. The only positive finding was the elevation of creatinine kinase (CK) (236 U/L) and CK-MB (29 U/L). She was then diagnosed with Guillain-Barre syndrome and largely recovered after high-dose glucocorticoid therapy.
Clinical findings
Now the patient has been admitted to our hospital with a recurrence of neurological symptoms in the past 1 month. Neurological examination of the patient showed not only muscle weakness and hypotonia of extremities, but also muscle weakness of neck flexion [Medical Research Council (MRC) grade 4], elbow flexion (MRC grade 3) and knee extension (MRC grade 4). In addition, no tendon reflexes of the biceps brachii and triceps were found. No significant abnormalities were observed in cranial nerve examination, sensory system, autonomic nervous system, and meningeal irritation sign.
Timeline
The timeline of this case report was shown below (Table 1; Figure 1).
Table 1
| Times | Events |
|---|---|
| First hospital admission in 2012. | First appearance of muscle weakness in the lower extremities. Diagnosed with Guillain-Barre syndrome and treated with glucocorticoid therapy. Symptoms were largely recovered. |
| Second hospital admission in 2019 (Figure 1). | Recurrence of muscle weakness in the lower extremities. Misdiagnosed with Guillain-Barre syndrome and treated with glucocorticoid therapy. Diagnosed with mitochondrial disorder and treated with corresponding therapy to regulate energy metabolism. Symptoms were gradually recovered. |
Timeline of this case report.
Figure 1
Diagnostic assessment
Laboratory analysis revealed elevated CK (246 U/L) and alpha-hydroxybutyrate dehydrogenase (alpha-HBDH) (232 U/L) levels in the patient. Results of other routine serologic investigations, cerebrospinal fluid (CSF) analysis, and autoimmune antibody titers, including peripheral neuropathy antibody spectrum in both serum and cerebrospinal fluid, were within normal limits. Electrocardiography revealed sinus tachycardia and left ventricular high voltage. Electromyography (EMG) and evoked potential (EP) suggested peripheral neurogenic damage of upper and lower extremities with myogenic damage. At the moment, the diagnosis of myopathy could not be ruled out, so we completed myositis autoantibody analysis and muscle magnetic resonance imaging (MRI). No myositis autoantibody was found. Under MRI scans (Figure 2), the characteristics of muscle lesions were not remarkable, and no obvious specific change in muscle group was found. However, there was edema in short-tau inversion recovery (STIR) sequences. Just then, a slight increase of blood lactic acid (8.7 mmol/L) was found in resting state, raising the suspicion of hereditary metabolic myopathy. Based on MRI finding, the tissue involved was then subjected to a muscle biopsy. The results (Figure 3) suggested pathological changes in MIDs and neuronal damage. So we thought MID might be the final diagnosis. In order to further clarify the diagnosis, mitochondrial DNA was carried out on the muscles involved and the results showed that there was a heteroplasmic m3271 T>C mutation in the mitochondrial tRNA-Leu gene (UUR), and the proportion of mutant mtDNA reached 87.4%.
Figure 2
Figure 3
Therapeutic intervention
According to MID diagnostic criteria in 2002, the patient met two main diagnostic indexes and could be diagnosed as MID with MELAS (3). After the diagnosis was confirmed, coenzyme Q10, vitamin B1, idebenone, and L-carnitine oral liquid were given to improve the function of the oxidative respiratory chain and regulate energy metabolism (Figure 1).
Follow-up and outcomes
After the treatment, the patient's symptoms had obviously improved and she could gradually stand and walk on her own. At 1-month follow-up, the muscle strength of neck flexion, elbow flexion and knee extension had recovered to MRC grade 5-/5.
Discussion
MELAS is one of the most common maternal MIDs. Approximately 80% of MELAS patients harbor m3243A>G mutation, while ~7 to 15% of MELAS patients carry m3271T>C mutation (4–6). Peripheral nerve dysfunction alone was extremely rare for MELAS patients. To the best of our knowledge, this is the first report of patient with MELAS with T3271C mitochondrial mutation who presented only as motor impairment movement. We believe that this case is meaningful for further understanding of MELAs with m3271T>C mutation in clinical settings.
The treatment of MELAS aims to improve mitochondrial function and regulate energy metabolism. In addition, drugs that affect mitochondrial function should be used with caution. Meanwhile, the guidelines for the diagnosis and treatment of MIDs do not recommend the use of glucocorticoid (GC), but in fact, MELAS patients appear to benefit from the use of GCs (7). In line with them, the MELAS patient in our case showed an improvement in muscle strength after GC therapy in the early stages of the disease. One possible explanation for this is that GCs are involved in mitochondrial regulation by acting directly on mitochondrial DNA through the mitochondrially localized glucocorticoid receptor (GR) or indirectly through interaction with nuclear genes (8, 9). Worth mentioning, MELAS associated with pure motor CIDP, a type of atypical CIDP, couldn't be ruled out in our case (10), which may explain the effectiveness of GCs. If necessary, a nerve biopsy may be performed to confirm the diagnosis of CIDP. Close metabolic monitoring of the patient is crucial when the patient has worsening symptoms or new symptoms of other organs. Further, first-degree relatives of the patient were recommended for lactic acid detection and genetic testing.
In conclusion, MELAS is sometimes misdiagnosed as CIDP because of similar clinical manifestations, which may lead to the delayed treatment and missed diagnosis of the patient's family. If necessary, muscle biopsy and mitochondrial DNA analyses should be performed for differential diagnosis.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.
Ethics statement
Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
D-hC, WL, H-sJ, and CY contributed to conception, design, acquisition of data, and analysis and interpretation of data. D-hC wrote the first draft of the manuscript. CY and H-sJ were responsible for revising manuscript. All authors contributed to read the manuscript and approved the submitted version.
Funding
This study was supported by the National Natural Science Foundation of China (Grant No. 82001315), Science and Technology Planning Project of Guangzhou (Grant No. 202102020832), and Medical Scientific Research Foundation of Guangdong Province (Grant No. C2023066).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
ArenaIGPuglieseAVoltaSToscanoAMusumeciO. Molecular genetics overview of primary mitochondrial myopathies. J Clin Med. (2022) 11:632. 10.3390/jcm11030632
2.
LaxNZGormanGSTurnbullDM. Review: central nervous system involvement in mitochondrial disease. Neuropathol Appl Neurobiol. (2017) 43:102–18. 10.1111/nan.12333
3.
BernierFPBonehADennettXChowCWClearyMAThorburnDR. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology. (2002) 59:1406–11. 10.1212/01.WNL.0000033795.17156.00
4.
GotoYNonakaIHoraiS. A mutation in the Trna(Leu)(Uur) gene associated with the melas subgroup of mitochondrial encephalomyopathies. Nature. (1990) 348:651–3. 10.1038/348651a0
5.
GotoYNonakaIHoraiSA. New Mtdna mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (melas). Biochim Biophys Acta. (1991) 1097:238–40. 10.1016/0925-4439(91)90042-8
6.
SakutaRGotoYHoraiSNonakaI. Mitochondrial dna mutations at nucleotide positions 3243 and 3271 in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: a comparative study. J Neurol Sci. (1993) 115:158–60. 10.1016/0022-510X(93)90219-O
7.
FinstererJFrankM. Glucocorticoids for mitochondrial disorders. Singapore Med J. (2015) 56:122–3. 10.11622/smedj.2015026
8.
LeeSRKimHKSongISYoumJDizonLAJeongSHet al. Glucocorticoids and their receptors: insights into specific roles in mitochondria. Prog Biophys Mol Biol. (2013) 112:44–54. 10.1016/j.pbiomolbio.2013.04.001
9.
PsarraAMSekerisCE. Glucocorticoids induce mitochondrial gene transcription in Hepg2 cells: role of the mitochondrial glucocorticoid receptor. Biochim Biophys Acta. (2011) 1813:1814–21. 10.1016/j.bbamcr.2011.05.014
10.
LehmannHCBurkeDKuwabaraS. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. (2019) 90:981–7. 10.1136/jnnp-2019-320314
Summary
Keywords
MELAS, T3271C mutation, peripheral nerve dysfunction, glucocorticoid therapy, case report
Citation
Chen D, Li W, Jiang H and Yuan C (2023) Case report: MELAS and T3271C mitochondrial mutation in an adult woman. Front. Neurol. 14:1179992. doi: 10.3389/fneur.2023.1179992
Received
05 March 2023
Accepted
10 July 2023
Published
27 July 2023
Volume
14 - 2023
Edited by
Giovanni Meola, University of Milan, Italy
Reviewed by
Jae Eun Sim, University of California, Irvine, United States; Corrado Italo Angelini, University of Padua, Italy
Updates
Copyright
© 2023 Chen, Li, Jiang and Yuan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hai-shan Jiang jianghs@smu.edu.cnChao Yuan yuanchao613@163.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.